Login | Register

Sector: Life Sciences

Patent families sold for $83,000 average in latest AST IP3 sale
Patent families sold for $83,000 average in latest AST IP3 sale

One patent seller seeking $1 billion didn’t find a buyer among the likes of AST members Cisco, Google and Microsoft, however, 36 deals were done which garnered $3.12 million

First unitary patent assertion occurs on UPC day one, as 10x Genomics follows up on German success
First unitary patent assertion occurs on UPC day one, as 10x Genomics follows up on German success

After winning first ever biotech AASI, 10x Genomics files first ever UP lawsuit

Life Sciences correspondent

Thought leadership from industry experts

Latest updates

EPO Enlarged Board of Appeal confirms use of post-published data to support inventive step
Latest content

New head of Mexican IP office begins work amid IP community concerns

Director General José Sánchez Pérez meets with local lawyers to discuss enforcement and implementation of IP law

25 January 2023

We are willing to litigate our CRISPR patents, says IP chief on the CVC side

ERS Genomics’ Michael Arciero shares his views on the Cas9 licensing landscape in an exclusive IAM interview

24 January 2023

Despite Teva’s English court of appeal defeat, Arrow declarations remain a valuable weapon for generics

The judgment is one of only a few decisions addressing the pre-emptive litigation defence

19 January 2023

Prepare now: call to action for chief IP officers on draft FTC non-compete policy

Commission may face legal challenges but risks of trade secrets breaches and increased litigation abound

13 January 2023

What BioNTech’s £362 million AI acquisition says about the future of life sciences IP strategies

The convergence of tech and biopharma has major implications for patent professionals

13 January 2023

SCOTUS will not hear $1.2 billion written description appeal, despite landmark enablement review

The court rejected Juno Therapeutics’ appeal, despite claims of similarity with Amgen v Sanofi dispute

11 January 2023

Royalty Pharma strikes another $1 billion dollar deal to acquire patent-backed revenue rights

Sales of drug earnings streams is an increasingly popular means of monetising life sciences innovations

10 January 2023

Novartis $245 million pay-out is latest reminder of pay-for-delay risks

Patent litigation settlements face increasingly dangerous antitrust pitfalls

09 January 2023

USPTO director welcomes turn of year with wave of patent battle decisions

Kathi Vidal will conduct a sua sponte review in Samsung vs Netlist and issued updates on VLSI IPR abuse reviews

06 January 2023

Brazil’s Supreme Court deals blow to rights holders on patent terms

A similar, separate case this year may still trigger a change of course, however

06 January 2023

Unlock unlimited access to all IAM content

Subscribe Now